Prosensa Holding N.V

The momentum that biopharmaceutical companies gained in the eyes of investors in 2020 continued into 2021, delivering a record number of initial public offerings in the US for the second year in a row

After signing a deal with Mallinckrodt PLC on the first anniversary of becoming CEO of Silence Therapeutics PLC David Horn Solomon has been reflecting on how transformational the pact will be and

Having been turned back twice by the European regulators in its pursuit of a Duchenne muscular dystrophy (DMD) indication for Raxone (idebenone), Santhera Pharmaceuticals AG has published the real

In any other circumstance, the US FDA's Peripheral & CNS Drugs Advisory Committee’s Sept. 28 meeting on PTC Therapeutics Inc. ’s ataluren would have been one that most sponsors could afford to skip